Yuki Kageyama to Urothelium
This is a "connection" page, showing publications Yuki Kageyama has written about Urothelium.
Connection Strength
1.244
-
Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
Score: 0.923
-
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. Anticancer Res. 2022 Feb; 42(2):1131-1136.
Score: 0.183
-
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006 Jun; 97(6):1322-6.
Score: 0.062
-
PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 2002 Jun; 191(3):310-9.
Score: 0.047
-
The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007 Aug; 100(2):269-73.
Score: 0.016
-
Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5501-7.
Score: 0.013